Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study

Eur J Cancer. 2017 Nov:85:114-121. doi: 10.1016/j.ejca.2017.07.023. Epub 2017 Sep 15.

Abstract

Background: Angiosarcomas are rare and aggressive soft-tissue sarcomas. The only potential curative treatment is complete surgical excision. This study reports the outcome of isolated limb perfusion (ILP) with high-dose melphalan and tumour necrosis factor α for locally advanced angiosarcoma.

Material and methods: All patients who underwent an ILP for angiosarcomas between 1991 and 2016 in three tertiary referral centres were identified from prospectively maintained databases.

Results: A total of 39 patients were included, with a median follow-up of 18 months (interquartile range 6.1-60.8). Of these patients, 23 (58.9%) patients had a complete response (CR) after ILP, 10 (25.6%) had a partial response, 4 (10.3%) had stable disease and 2 (5.1%) patients had progressive disease immediately after ILP. A total of 22 patients developed local progression (56.4%), whereas nine (23.1%) developed distant metastases. The patients with CR had a significantly prolonged median local progression-free survival (PFS) (15.4 versus 7.3 months, p = 0.015) when compared with non-CR patients, and a trend towards better median overall survival (81.2 versus 14.5 months, p = 0.054). Six patients underwent multiple ILPs, whereby the CR rate of the first, second and third ILPs were 60%, 80% and 67%, respectively. Thirteen (33.3%) patients needed further surgical intervention, consisting of resection in eight patients (20.5%) and amputation in five patients (12.8%).

Conclusion: ILP is an effective treatment option for patients with locally advanced angiosarcoma in the extremities, resulting in a high number of CRs, a high limb salvage rate and prolonged local PFS.

Keywords: Angiosarcoma; Cutaneous angiosarcoma of the extremity; ILP; Isolated limb perfusion; Limb salvage technique; Locally advanced angiosarcoma; Sarcoma.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Amputation, Surgical
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chemotherapy, Cancer, Regional Perfusion / adverse effects
  • Chemotherapy, Cancer, Regional Perfusion / methods*
  • Chemotherapy, Cancer, Regional Perfusion / mortality
  • Databases, Factual
  • Disease Progression
  • Disease-Free Survival
  • Extremities / blood supply*
  • Extremities / pathology
  • Female
  • Hemangiosarcoma / blood supply*
  • Hemangiosarcoma / mortality
  • Hemangiosarcoma / secondary
  • Hemangiosarcoma / therapy*
  • Humans
  • Kaplan-Meier Estimate
  • Limb Salvage
  • London
  • Male
  • Melphalan / administration & dosage*
  • Melphalan / adverse effects
  • Middle Aged
  • Netherlands
  • Proportional Hazards Models
  • Regional Blood Flow
  • Retreatment
  • Retrospective Studies
  • Risk Factors
  • Soft Tissue Neoplasms / blood supply*
  • Soft Tissue Neoplasms / mortality
  • Soft Tissue Neoplasms / pathology
  • Soft Tissue Neoplasms / therapy*
  • Time Factors
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / administration & dosage*
  • Tumor Necrosis Factor-alpha / adverse effects
  • Young Adult

Substances

  • Tumor Necrosis Factor-alpha
  • Melphalan